Shorter radiation with medication for older adults with colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation therapy combined with medication for older or frail patients with colorectal cancer that cannot be removed by surgery. The goal is to control the cancer while reducing side effects and improving quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older, or 60–69 with some frailty or health issues.
- You have colorectal cancer that has not spread to distant organs.
- You are not able to have surgery to remove the cancer, or you choose not to.
- You have not had radiation to the same area before, and you have not had chemotherapy or immunotherapy for this cancer.
- You have adequate blood counts and liver/kidney function.
- You do not have other serious uncontrolled medical conditions (like active heart disease or autoimmune diseases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way of giving radiation therapy in smaller, more frequent doses along with your first round of systemic treatment (chemo or other drugs) for metastatic colorectal cancer. The goal is to find a treatment that is effective and easier for older or frailer patients to tolerate.
This trial studies a special type of radiation therapy for older adults with rectal cancer who are not able or willing to have surgery. It combines external beam radiation with a short, focused radiation treatment inside the rectum (brachytherapy) to try to control the cancer while avoiding the risks of surgery.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests a new combination of short-course radiation, a targeted drug (fruquintinib), and an immunotherapy drug (PD-1 inhibitor) to treat rectal cancer before surgery. It aims to shrink the tumor and improve outcomes for patients with a specific type of rectal cancer.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.